Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2018

View Archived Issues

Bioverativ conducts phase III trials with BIVV-009 in primary cold agglutinin disease

Green Cross LabCell and Feldan Therapeutics collaborate to develop NK cell immunotherapies

DNA repair-related biomarkers induced by alcohol have prognostic value in gastric cancer

The Salk Institute and Indivumed enter alliance to advance global cancer research

Tenax Therapeutics to develop levosimendan for PH-HFpEF

GigaGen awarded NIH grant to develop technology for rIVIG therapy

Centrexion Therapeutics' CNTX-4975 receives FDA fast track designation

ShangPharma Innovation enters multi-year strategic collaboration

Foundation Medicine, Pfizer partner to develop companion diagnostics

Jounce Therapeutics reviews its next-generation immunotherapy pipeline

U.S. priority review and E.U. accelerated assessment granted for Kymriah

FDA accepts Ruconest sBLA for review

Rxi Pharmaceuticals to focus on immuno-oncology

Gamida Cell commences phase I study of NAM-NK cells in NHL and MM

Context Therapeutics acquires Apristor from Arno Therapeutics

Final results reported from phase II study of Bekinda in IBS-D

AvantGen begins second cancer therapeutic antibody discovery program with Tanabe Research Labs

Abide Therapeutics gives an overview of their serine hydrolase-targeting products

Phase II LIBERTY study of ubenimex in PAH does not meet primary endpoint

Athenex gets positive feedback from FDA on phase III Oraxol study design

Zhejiang Palo Alto Pharmaceuticals divulges new NS5A inhibitors

FDA grants fast track designation to Aspyrian's RM-1929 in head and neck cancer

Almirall presents novel JAK inhibitors

Chinese reserachers disclose IDH1 inhibitors

Novel compounds for HBV presented by Roche

The Vanderbilt University divulges M4 receptor PAMs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...